- Home
- IMMX vs ATRA Comparison
IMMX vs ATRA Comparison
Compare IMMX & ATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMMX
- ATRA
- Stock Information
- Founded
- IMMX 2014
- ATRA 2012
- Country
- IMMX United States
- ATRA United States
- Employees
- IMMX N/A
- ATRA N/A
- Industry
- IMMX Medicinal Chemicals and Botanical Products
- ATRA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IMMX Health Care
- ATRA Health Care
- Exchange
- IMMX Nasdaq
- ATRA Nasdaq
- Market Cap
- IMMX 46.8M
- ATRA 50.3M
- IPO Year
- IMMX 2021
- ATRA 2014
- Fundamental
- Price
- IMMX $1.67
- ATRA $11.25
- Analyst Decision
- IMMX Strong Buy
- ATRA Hold
- Analyst Count
- IMMX 1
- ATRA 5
- Target Price
- IMMX $7.00
- ATRA $26.88
- AVG Volume (30 Days)
- IMMX 89.1K
- ATRA 143.9K
- Earning Date
- IMMX 11-12-2024
- ATRA 11-12-2024
- Dividend Yield
- IMMX N/A
- ATRA N/A
- EPS Growth
- IMMX N/A
- ATRA N/A
- EPS
- IMMX N/A
- ATRA N/A
- Revenue
- IMMX N/A
- ATRA $100,439,000.00
- Revenue This Year
- IMMX N/A
- ATRA $1,190.80
- Revenue Next Year
- IMMX $200.00
- ATRA N/A
- P/E Ratio
- IMMX N/A
- ATRA N/A
- Revenue Growth
- IMMX N/A
- ATRA 2111.34
- 52 Week Low
- IMMX $1.26
- ATRA $6.50
- 52 Week High
- IMMX $7.75
- ATRA $39.50
- Technical
- Relative Strength Index (RSI)
- IMMX 50.69
- ATRA 51.65
- Support Level
- IMMX $1.65
- ATRA $10.03
- Resistance Level
- IMMX $1.93
- ATRA $14.93
- Average True Range (ATR)
- IMMX 0.16
- ATRA 1.33
- MACD
- IMMX 0.01
- ATRA -0.18
- Stochastic Oscillator
- IMMX 42.55
- ATRA 25.96
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
About ATRA Atara Biotherapeutics Inc.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).